Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.
Actively Recruiting
Researchers are evaluating the EkiYou V2 Digital Therapy in adults with diabetes who use multiple daily insulin injections as part of a basal-bolus insulin regimen. This multicenter randomized controlled trial aims to compare the performance of this digital therapy with conventional insulin management methods and assess user satisfaction and quality of life. The study is sponsored by DiappyMed and follows 154 adults over a 6-month period. Participants will be randomly assigned to either receive the EkiYou V2 device at the start or continue their standard basal-bolus insulin care for three months before switching to the device for the remaining three months. The EkiYou V2 is a mobile application that supports insulin dose estimation, including basal insulin dose, insulin-to-carb ratios, and correction factors. It uses a large food database, accounts for meals, physical activity, and glucose levels, and connects to continuous glucose monitoring CGM devices. During the 6-month study, participants will attend three visits and complete electronic questionnaires to report their quality of life and satisfaction with the application. Researchers will monitor glucose control through CGM data, measuring time spent in the target glucose range and other glucose-related outcomes. Safety events and adverse effects related to the device will also be tracked throughout the trial.
Actively Recruiting
This research aims to evaluate whether adjusting the mean arterial pressure MAP target based on central venous pressure CVP can improve organ function and survival in adults with cardiogenic shock, a serious condition where the heart cannot pump enough blood, leading to organ damage and high death rates. The study compares personalized MAP targets to the standard MAP target to see if individualizing blood pressure goals can better protect organs and improve outcomes. Participants receive blood pressure management in one of two ways either a personalized MAP target calculated as 65 mmHg plus the measured CVP range 65-75 mmHg plus CVP, not exceeding 90 mmHg, or a standard MAP target of 65-70 mmHg following current guidelines. CVP is measured through a central venous catheter. After 48 hours, the personalized MAP target may be lowered if tissue perfusion has improved. Throughout the study, participants are monitored for survival, organ function, and need for mechanical support over 7, 28, and 90 days. Researchers assess mortality, kidney failure, use of circulatory support and dialysis, as well as various clinical scores and complications like arrhythmias and bleeding. The primary outcome combines death, use of mechanical circulatory support, and severe kidney failure. The study is randomized and will last until July 2029.
Actively Recruiting
Researchers are evaluating the ongoing safety, glycemic control, quality of life, and usage rate of the Control-IQ System in people with type 1 diabetes in France. This post-market surveillance study aims to monitor severe metabolic complications such as severe hypoglycemia and diabetic ketoacidosis over 12 months of real-world use. It is a single-arm, prospective cohort study that includes all approved populations using the system. Participants will use the tslim X2 insulin pump with Control-IQ technology combined with a Dexcom G6 or G7 continuous glucose monitoring sensor. They will follow standard care and continue use of the system for at least 12 consecutive months after enrollment. The study gathers data on device performance, patient satisfaction, usability, and quality of life throughout this period. During the study, participants will provide clinical data including HbA1c results from up to 4 months prior and during the study period. They will complete questionnaires about treatment satisfaction, system usability, quality of life, and fear of hypoglycemia. Researchers will measure rates of diabetic ketoacidosis and severe hypoglycemia, time spent in target glucose ranges, and system usage. The total participation duration is 12 months, with safety and device use closely monitored.